Key result
The hERG potassium channel serves as a critical therapeutic target and liability in antiarrhythmic pharmacotherapy, long QT syndrome, and other diseases, guiding future drug design.
Design
Review
Authors
Loading...
hERG liability screening remains essential in drug development; leaves open selective modulation strategies for channelopathies.
The hERG potassium channel is a critical target in antiarrhythmic pharmacotherapy and the pathogenesis of long and short QT syndromes, with ongoing efforts to design out hERG liability in drug development.
Harry J. Witchel (2007) conducted a review in Arrhythmia and long QT syndrome (LQTS). hERG potassium channel blockade was evaluated. The hERG potassium channel serves as a critical therapeutic target and liability in antiarrhythmic pharmacotherapy, long QT syndrome, and other diseases, guiding future drug design.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: